Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Zealand Pharma A/S is seeking a Head of Pharmacometrics to establish a standalone, strategic pharmacometrics capability within Medical & Science. You will lead model-informed drug development as the operating principle, owning quantitative dose selection and study design across portfolios, with a focus on early clinical development.
You will define standards, recruit a team, and collaborate across Clinical Pharmacology, Translational Medicine, Medical, Biostatistics, Regulatory Affairs and
Does it excite you to build a pharmacometrics function from the ground up, and do you have experience making model-informed drug development the way decisions get made? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague. As Head of Pharmacometrics, you will establish and lead pharmacometrics as a standalone, strategic capability within Medical & Science in Development & Manufacturing Sciences. You will be the key leader for implementing model-informed drug development (MIDD) as the operating principle of our development organization. The role owns the quantitative basis for dose selection, study design and candidate progression across the portfolio, with a focus on early clinical development. This is a founding role with the mandate to define the function, set the standards and recruit the team.
You are a scientifically rigorous builder who is energized by creating something new and operates comfortably with ambiguity. You can translate complex modelling into clear recommendations for senior decision-makers, and you lead change by influencing how an organization makes decisions, not only how models are built. You collaborate easily across sites, time zones and partner organizations, and you take ownership and act boldly.
You will report to the SVP, Medical & Science, and join the Medical & Science leadership team within Development & Manufacturing Sciences. As the founding leader of a new unit, you will start without direct reports and build the team as the function grows. You will work closely with Clinical Pharmacology, Translational Medicine, Medical, Biostatistics, Regulatory Affairs, Discovery Research and Patient Safety. The portfolio spans a Phase 3 obesity program co-developed with a global partner and a growing early-stage pipeline moving into the clinic.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold. We are committed to an inclusive recruitment process and welcome applications from all job applicants.
About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.
We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.